Biomedical Research Education & Training
Faculty Member

Mayer, Ingrid A., M.D.
Associate Professor of Medicine

Lab Url: http://medicine.mc.vanderbilt.edu/divisions/hemonc/search_kaiser2.cfm?PI=1305

Phone Number: (615) 322-4967

Email Address: ingrid.mayer@vanderbilt.edu

Mayer, Ingrid's picture
Academic history
Doctor of Medicine (M.D), Federal University of Sao Paulo, Brazil
Internal Medicine Residency, University of Illinois at Chicago
Internal Medicine Chief Residency, University of Illinois at Chicago
Hematology/ Oncology Fellowship, University of Illinois at Chicago
Master of Science in Clinical Investigation (M.S.C.I.), Vanderbilt University School of Medicine

Office Address   Mailing Address

790 PRB Vanderbilt - Ingram Cancer Center; 2220 Pierce Avenue, Nashville, TN 37232

Vanderbilt - Ingram Cancer Center 777 Preston Research Building 37232


Research Keywords
Breast Cancer,Cancer,Translation

Clinical Research Keywords
Breast Cancer - Targeted Therapies

Patient Care Specialty
Medical Oncology - Breast Cancer

Research Specialty
Breast Cancer - Targeted Therapies

Research Description
My research focus is on new therapeutic strategies focusing on the phosphatidylinositol-3 kinase (PI3K)/Akt and correlated pathways in triple-negative, hormone-refractory and HER2-overexpressing refractory breast cancers, using biologically-based targeted agents. I plan to perform molecular analysis of individual breast cancers in an attempt to determine how the biology of the cancer affects the response to the therapeutic agent. It is also my goal to play a key role in elucidating mechanisms of therapy resistance for patients with triple-negative, resistant ER-positive and resistant HER2-positive breast cancers. Ultimately this will result in better and more rational patient/therapy selection.

My role as a clinical investigator are as follows:
1) Develop a Clinical Breast Cancer Research Program with strong links to laboratory efforts throughout the medical center and if necessary, external to the institution. This goal involves collaboration with prestigious investigators within and outside Vanderbilt, and consists of a bidirectional process: observations made in the clinic and correlative studies in tissue samples from clinical trial patients with breast cancer lead basic scientists to investigate new areas of research. Conversely, pre-clinical data focused on relevant signaling pathways in breast cancer are the basis for development and implementation of novel hypothesis-driven clinical trials.
2) Expand preclinical therapeutic testing with tumors freshly obtained from the breast cancer patients in clinical trials. Tissue collection (primary tumor paraffin blocks and/or fresh frozen tissue) in all investigator-initiated breast cancer clinical trials is required for patient enrollment. Thanks to our Multidisciplinary Breast Cancer Clinic, we have been extremely successful in enrolling patients to clinical trials requiring research biopsies.
3) Develop and perform hypothesis-driven, translational clinical trials with biologically-based targeted therapeutics that are based on preclinical findings obtained in vitro and/or in vivo in human and murine systems, to address the most important issues in breast cancer .

My research endeavors are focused on the role of the following correlated key cell signaling pathways in breast cancer: PI3K/Akt, erbB (EGFR, HER2/neu), and Insulin-like Growth Factor (IGF)-1 pathways. I have developed targeted-oriented clinical trials addressing the role of these pathways in the development of resistance to antiestrogens and trastuzumab, as well as their role in triple-negative, basal-like tumors. This strategy will provide better understanding of breast cancer biology and of the molecular determinants of clinical efficacy, by optimally characterizing the molecular features of the breast cancer to be treated. This will foster target-assay development in a more limited number of patients. In turn, these results will be instrumental in expediting subsequent development of molecularly targeted agents, providing a platform for prioritization of novel combinations and elucidation of preferential mechanisms of escape from these therapies.

Examples of some of my investigator-initiated clinical trials include:

VICCBRE0949: A phase I/II study of cisplatin, paclitaxel and RAD001 in patients with metastatic breast cancer

VICCBRE0904: A phase II neoadjuvant study of cisplatin, paclitaxel with or without RAD001 in patients with triple-negative locally advanced breast cancer

VICCBRE09112: A phase II trial of endocrine therapy in combination with OSI-906 (an IGF-1R inhibitor) and erlotinib (Tarcevaa??, an EGFR inhibitor) in patients with hormone-sensitive metastatic breast cancer

VICCBRE0942: A pre-surgical trial of metformin in patients with operable early breast cancer

VICCBRE0983: A Prospective Clinical Trial evaluating Potential Biomarkers for Bevacizumab Induced Hypertension

Clinical Research Description
My research focus is on new therapeutic strategies focusing on the phosphatidylinositol-3 kinase (PI3K)/Akt and correlated pathways in triple-negative, hormone-refractory and HER2-overexpressing refractory breast cancers, using biologically-based targeted agents. I plan to perform molecular analysis of individual breast cancers in an attempt to determine how the biology of the cancer affects the response to the therapeutic agent. It is also my goal to play a key role in elucidating mechanisms of therapy resistance for patients with triple-negative, resistant ER-positive and resistant HER2-positive breast cancers. Ultimately this will result in better and more rational patient/therapy selection.

My role as a clinical investigator are as follows:
1) Develop a Clinical Breast Cancer Research Program with strong links to laboratory efforts throughout the medical center and if necessary, external to the institution. This goal involves collaboration with prestigious investigators within and outside Vanderbilt, and consists of a bidirectional process: observations made in the clinic and correlative studies in tissue samples from clinical trial patients with breast cancer lead basic scientists to investigate new areas of research. Conversely, pre-clinical data focused on relevant signaling pathways in breast cancer are the basis for development and implementation of novel hypothesis-driven clinical trials.
2) Expand preclinical therapeutic testing with tumors freshly obtained from the breast cancer patients in clinical trials. Tissue collection (primary tumor paraffin blocks and/or fresh frozen tissue) in all investigator-initiated breast cancer clinical trials is required for patient enrollment. Thanks to our Multidisciplinary Breast Cancer Clinic, we have been extremely successful in enrolling patients to clinical trials requiring research biopsies.
3) Develop and perform hypothesis-driven, translational clinical trials with biologically-based targeted therapeutics that are based on preclinical findings obtained in vitro and/or in vivo in human and murine systems, to address the most important issues in breast cancer .

My research endeavors are focused on the role of the following correlated key cell signaling pathways in breast cancer: PI3K/Akt, erbB (EGFR, HER2/neu), and Insulin-like Growth Factor (IGF)-1 pathways. I have developed targeted-oriented clinical trials addressing the role of these pathways in the development of resistance to antiestrogens and trastuzumab, as well as their role in triple-negative, basal-like tumors. This strategy will provide better understanding of breast cancer biology and of the molecular determinants of clinical efficacy, by optimally characterizing the molecular features of the breast cancer to be treated. This will foster target-assay development in a more limited number of patients. In turn, these results will be instrumental in expediting subsequent development of molecularly targeted agents, providing a platform for prioritization of novel combinations and elucidation of preferential mechanisms of escape from these therapies.

Examples of some of my investigator-initiated clinical trials include:

VICCBRE0949: A phase I/II study of cisplatin, paclitaxel and RAD001 in patients with metastatic breast cancer

VICCBRE0904: A phase II neoadjuvant study of cisplatin, paclitaxel with or without RAD001 in patients with triple-negative locally advanced breast cancer

VICCBRE09112: A phase II trial of endocrine therapy in combination with OSI-906 (an IGF-1R inhibitor) and erlotinib (Tarcevaa??, an EGFR inhibitor) in patients with hormone-sensitive metastatic breast cancer

VICCBRE0942: A pre-surgical trial of metformin in patients with operable early breast cancer

VICCBRE0983: A Prospective Clinical Trial evaluating Potential Biomarkers for Bevacizumab Induced Hypertension

Clinical Interests
Dr. Mayer is a medical oncologist who specializes in breast cancer. Her research focus is clinical and translational correlative studies in Breast Cancer. She is primarily involved with development of clinical trials addressing novel effective combinations of chemotherapy and biological agents for treatment and prevention, and identification of new markers and predictors of disease.

Her research endeavors have been focused on the role of the following correlated key cell signaling pathways in breast cancer: PI3K/Akt, erbB (EGFR, HER2/neu), and Insulin-like Growth Factor (IGF)-1 pathways. She has been developing hypothesis-driven, translational clinical trials with biologically-based targeted therapeutics that are based on preclinical findings obtained in vitro and/or in vivo in human and murine systems. This will facilitate the process of identifying new molecular targets with prognostic and therapeutic value, and in elucidating mechanisms of therapy resistance for patients with triple-negative, resistant ER-positive and resistant HER2-positive breast cancers.

Publications
Bauer, JA, Chakravarthy, AB, Rosenbluth, JM, Mi, D, Seeley, EH, De Matos Granja-Ingram, N, Olivares, MG, Kelley, MC, Mayer, IA, Meszoely, IM, Means-Powell, JA, Johnson, KN, Tsai, CJ, Ayers, GD, Sanders, ME, Schneider, RJ, Formenti, SC, Caprioli, RM, Pietenpol, JA. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res, 16(2), 681-90, 2010

Mayer, IA, Arteaga, CL. Does lapatinib work against HER2-negative breast cancers. Clin Cancer Res, 16(5), 1355-7, 2010

Carlson, RW, Allred, DC, Anderson, BO, Burstein, HJ, Carter, WB, Edge, SB, Erban, JK, Farrar, WB, Goldstein, LJ, Gradishar, WJ, Hayes, DF, Hudis, CA, Jahanzeb, M, Kiel, K, Ljung, BM, Marcom, PK, Mayer, IA, McCormick, B, Nabell, LM, Pierce, LJ, Reed, EC, Smith, ML, Somlo, G, Theriault, RL, Topham, NS, Ward, JH, Winer, EP, Wolff, AC, , . Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw, 7(2), 122-92, 2009

Li, X, Dawant, BM, Welch, EB, Chakravarthy, AB, Freehardt, D, Mayer, I, Kelley, M, Meszoely, I, Gore, JC, Yankeelov, TE. A nonrigid registration algorithm for longitudinal breast MR images and the analysis of breast tumor response. Magn Reson Imaging, 27(9), 1258-70, 2009

Mayer IA, Burris HA, Bendell JC, Means-Powell J, Arteaga CL, Shyr Y, Pietenpol JA. . A phase Ib trial of RAD001, an mTOR inhibitor, with weekly cisplatin and paclitaxel in patients with HER2-negative metastatic breast cancer.. 32nd Annual San Antonio Breast Symposium, San Antonio, TX , abstract 3093, 2009

Mayer IA, Means-Powell J, Shyr Y, Arteaga CL. A phase Ib trial of Erlotinib, and EGFR inhibitor, and Everolimus (RAD001), an mTOR inhibitor, in patients with metastatic breast cancer. 32nd Annual San Antonio Breast Symposium, San Antonio, TX , abstract 3094, 2009

Mayer, IA. Treatment of HER2-positive metastatic breast cancer following initial progression. Clin Breast Cancer, 9 Suppl 2, S50-7, 2009

Planey, CR, Welch, EB, Xu, L, Chakravarthy, AB, Gatenby, JC, Freehardt, D, Mayer, I, Meszeoly, I, Kelley, M, Means-Powell, J, Gore, JC, Yankeelov, TE. Temporal sampling requirements for reference region modeling of DCE-MRI data in human breast cancer. J Magn Reson Imaging, 30(1), 121-34, 2009 PMCID:2782711

Pohlmann, PR, Mayer, IA, Mernaugh, R. Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res, 15(24), 7479-7491, 2009

Guix, M, Granja, Nde M, Meszoely, I, Adkins, TB, Wieman, BM, Frierson, KE, Sanchez, V, Sanders, ME, Grau, AM, Mayer, IA, Pestano, G, Shyr, Y, Muthuswamy, S, Calvo, B, Krontiras, H, Krop, IE, Kelley, MC, Arteaga, CL. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol, 26(6), 897-906, 2008 PMCID:2614851

Guix, M, Mayer, IA, Meszoely, IM, Arteaga, CL. Evaluation of biological agents targeted at early-stage disease. Breast Cancer Res, 10 Suppl 4, S25, 2008 PMCID:2614851

Yankeelov, TE, Lepage, M, Chakravarthy, A, Broome, EE, Niermann, KJ, Kelley, MC, Meszoely, I, Mayer, IA, Herman, CR, McManus, K, Price, RR, Gore, JC. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging, 25(1), 1-13, 2007 PMCID:2634832

Chakravarthy, AB, Kelley, MC, McLaren, B, Truica, CI, Billheimer, D, Mayer, IA, Grau, AM, Johnson, DH, Simpson, JF, Beauchamp, RD, Jones, C, Pietenpol, JA. Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. Clin Cancer Res, 12(5), 1570-6, 2006

Mayer IA. Targeting Cytokine Receptors and Pathways in the Treatment of Breast Cancer. Cytokines and Cancer, chapter 10(Platanias LC (ed). 2005 Springer Science + Business Media, Inc.), 243, 2005

Mayer, IA. Targeting cytokine receptors and pathways in the treatment of breast cancer. Cancer Treat Res, 126, 243-62, 2005

Rouch D, Mayer I, Truica C . Barriers to chemoprevention of breast cancer with tamoxifen. American Society of Clinical Oncology Proceedings, 41th Annual Meeting , abst 1010, 2005

Chakravarthy B, Kelley M, McLaren B, Truica C, Mayer I, Brown C, Johnson K, Simpson J, Billheimer D, Pietenpol JA. Developing markers of therapeutic response using serial core biopsies to paclitaxel/radiation in stage II/III breast cancer . Breast Cancer Research and Treatment, supplement 1 (San Antonio Breast Cancer Symposium ? 27th Annual Meeting - Special Issue)(88), S50 (abstract 1028), 2004

Costa FP, Schemerling R, Costa OF, Costa PA, Albertotti C, Martins S, Buzaid AC, Maluf F, Mayer I, Marques R . Intra-hepatic lipiodol I-131 combined with oxaliplatin, infusional FUDR, leucovorin in hepatocarcinoma and hepatic metastasis. ASCO Proceedings, 40th Annual Meeting, Abstract No 4133, 2004

Mayer IA. Locally Advanced Breast Cancer. Manual de Oncologia Clinica - Hospital Sirio Libanes - Cutait R, Buzaid AC (eds). Rio de Janeiro: Reichmann & Affonso Editores, 2nd edition, chapter 2, 2004

Mayer IA. Metastatic Breast Cancer. Manual de Oncologia Clinica - Hospital Sirio Libanes - Cutait R, Buzaid AC (eds). Rio de Janeiro: Reichmann & Affonso Editores, 2nd edition, chapter 3, 2004

Yamaguchi NH, Mayer IA, Malzyner A, Andrade CJC, Murad AM, Giglio AD, Cardoso H. . A pilot feasibility study of gefitinib (ZD1839) and celecoxib in metastatic GI tumors. ASCO Proceedings, 40th Annual Meeting, Abstract No 3086, 2004

Costa FC, Marques RJ, Mayer IA, Maluf FC, Martins SC, Cutait R, Buzaid AC. Irinotecan, Oxaliplatin and Raltitrexed every two weeks in untreated metastatic colorectal cancer patients. ASCO Proceedings , 38th Annual Meeting, Abstract No 2348, 2002

Grumbach, I M, Mayer, I A, Uddin, S, Lekmine, F, Majchrzak, B, Yamauchi, H, Fujita, S, Druker, B, Fish, E N, Platanias, L C. Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells. Br J Haematol, 112(2), 327-36, 2001

Mayer, I A, Verma, A, Grumbach, I M, Uddin, S, Lekmine, F, Ravandi, F, Majchrzak, B, Fujita, S, Fish, E N, Platanias, L C. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J Biol Chem, 276(30), 28570-7, 2001

Mayer IA, Grumbach IM, Fujita S, Uddin S, Platanias LC. Activation of the p38 Map kinase pathway mediates the growth inhibitory effects of IFN-alpha in Chronic Myelogenous Leukemia. Blood, 96(11), Abstract No 1500, 2000

Uddin S, Lekmine F, Sharma N, Majchrzak B, Mayer I, Young PR, Bokoch GM, Fish EN, Platanias LC . The Rac1/p38 Map kinase pathway is required for IFN-alpha dependent transcriptional activation but not serine phosphorylation of STAT-proteins. J Biol Chem, 275(36), 27634-40, 2000


Postdoctoral Position Available
N/A

Postdoctoral Position Details
N/A

Updated Date
04/20/2010